Imugene (ASX:IMU) reported a second complete response in the concurrent BTKi (Bruton Tyrosine Kinase inhibitor) cohort. The update suggests ongoing efficacy signals, but without any disclosed magnitude (e.g., response rate, duration, or timing) the near-term impact is likely limited.
Imugene (ASX:IMU) reported a second complete response in the concurrent BTKi (Bruton Tyrosine Kinase inhibitor) cohort. The update suggests ongoing efficacy signals, but without any disclosed magnitude (e.g., response rate, duration, or timing) the near-term impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
